SCHEMBL18362003

SCHEMBL18362003

NCc1cc(Oc2cccc(C(=O)Nc3ccccc3)c2)ncn1

nearest known ligand 0.70

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
LOXL2 Q9Y4K0 18/20 0.70
LOX P28300 12/20 0.70
KDR P35968 1/20 0.53
MAP2K7 O14733 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18362019 0.93 LOXL2 (0.71) LOXL2LOX
SCHEMBL18362036 0.85 LOXL2 (0.73) LOXL2LOX
SCHEMBL18361783 0.83 LOXL2 (0.64) LOXL2LOX
SCHEMBL18361791 0.83 LOXL2 (0.98) LOXL2LOXMAP2K7
Hydrochloric Acid SCHEMBL20337922 0.83 LOXL2 (0.66) LOXL2LOX
SCHEMBL18361815 0.82 LOXL2 (0.79) LOXL2LOX
SCHEMBL18049113 0.82 LOXL2 (1.00) LOXL2LOX
Hydrochloric Acid SCHEMBL20337925 0.82 LOXL2 (1.00) LOXL2LOX
SCHEMBL18362100 0.81 LOXL2 (0.65) LOXL2LOX
SCHEMBL18361817 0.81 LOXL2 (0.62) LOXL2LOX

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180186755-A1 LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF PHARMAKEA INC (US) 2018-07-05 US disclosed
US-20180186755-A1 LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF PHARMAKEA INC (US) 2018-07-05 US disclosed
WO-2017003862-A1 LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF PHARMAKEA, INC. (US) 2017-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180186755-A1 LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF LOXL2, LOXL1, LOX LOXL2 1/4885LOX 3/4885KDR 2668/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.